TL;DR
This paper tackles the challenge of drug repurposing by building a more comprehensive drug network. They achieve this by reinforcing an initial drug-target protein network with drug-drug interaction data, leading to improved drug recommendation accuracy for identifying new uses of existing drugs.
What Problem Does This Paper Address?
Drug discovery is an incredibly expensive and time-consuming process, often taking over a decade and costing hundreds of millions of dollars. Drug repurposing, the idea of finding new therapeutic uses for existing drugs, offers a promising alternative to de novo drug discovery. However, identifying these new uses computationally (in silico) is still challenging. Existing in silico methods often rely on sparse networks of drug information, limiting their effectiveness. This paper aims to overcome this limitation by creating a richer, more interconnected drug network that can lead to more reliable drug repurposing predictions.
Methods
The core of this work is a three-step approach:
- Drug Network Construction: They begin by building an initial drug network where drugs are nodes and edges represent similarities derived from shared drug-target protein information. This is a standard approach, but it often results in a sparse network because not all drug-target relationships are known.
- Network Reinforcement: To address the sparsity, they enhance the initial network using external data sources. This involves:
- Complementary Linkage with Anchoring and Scoring (CLASH): This algorithm is used to connect previously unconnected drugs. It works by "anchoring" isolated drugs to existing ones based on external knowledge and then scoring potential connections to confirm them.
- External Data Sources: They integrate drug-drug interaction knowledge from sources like PubChem and PubMed, specifically focusing on bioactivity and medication information. This adds crucial connections that were missing in the initial drug-target network.
- Drug Scoring: Once the enhanced network is built, they use a graph-based semi-supervised learning (SSL) algorithm to score drugs for a specific target disease. SSL is chosen because it can leverage both labeled (known drug-disease associations) and unlabeled data, making it suitable for sparse interaction data. The scoring algorithm assigns a priority rank to each drug, with higher scores indicating a greater potential for repurposing.
Datasets
The study utilizes several datasets:
- Drug and Disease Lists: 5442 drugs and 1938 diseases were obtained from PubChem and the National Library of Medicine's Medical Subject Headings (MeSH).
- Drug-Target Protein Information: 91,450 drug-target protein associations were used.
- Disease-Drug Association: 61,794 disease-drug associations were used for validation.
- Drug-Drug Interaction Data: 77,729 drug-drug interactions from PubChem and PubMed were used for network reinforcement.
The paper does not introduce new benchmark datasets but rather leverages existing, publicly available ones.
Key Insights and Ideas
- Network Sparsity is a Major Bottleneck: The paper clearly demonstrates that relying solely on drug-target protein information leads to sparse networks, limiting the ability to find meaningful connections for drug repurposing.
- External Data is Crucial for Enrichment: Integrating diverse sources of drug-drug interaction data significantly enriches the network, making it more comprehensive and informative.
- CLASH Algorithm's Effectiveness: The CLASH algorithm proves effective in connecting previously isolated drugs, increasing drug coverage and network density.
- SSL for Robust Drug Scoring: Semi-supervised learning is a powerful tool for drug scoring, especially when dealing with incomplete interaction data, as it can infer relationships from limited information.
- Reinforcement Improves Prediction Reliability: The enhanced network not only increases the number of connections but also leads to more reliable drug recommendations, as evidenced by improved performance metrics.
Key Results
- Increased Network Coverage: The enhanced network increased drug coverage from 4738 to 5442 drugs and drug-drug associations from 808,752 to 982,361.
- Improved Prediction Performance: The Area Under the ROC Curve (AUC) for drug repurposing prediction improved from 0.79 (original network) to 0.89 (enhanced network).
- Statistical Significance: The performance difference between the original and enhanced networks was statistically significant (p-values of 0.0003 and 0.0005 for comparisons with original and data fusion networks, respectively).
- Example Case Study (Vascular Dementia): The method successfully identified 11 candidate drugs for vascular dementia, including Amantadine and Conotoxin GV, with high confidence scores. The paper highlights how Amantadine's repurposing potential was revealed through its connection with memantine via drug-drug interaction data.
Limitations and Future Work
- Negative Correlation Ignored: The authors acknowledge that they did not consider the negative correlation of newly added connections, which could represent antagonistic properties. Future work could explore incorporating this.
- Personalization Potential: They suggest that personalizing the network with patient-specific genetic information could further enhance its utility for precision medicine.
- Expanding Knowledge Sources: The paper notes that expanding complementary knowledge sources to include drug side-effects and drug chemical structures could further improve the model.
Summary updated